We're moving into a time of year that’s been difficult for bulls, historically. However, if the market does sell off, Cramer won't cry.» Read More
NEW YORK, Sept 8- Mathew Martoma, a former portfolio manager at billionaire Steven A. Cohen's SAC Capital Advisors LP hedge fund, was sentenced on Monday to nine years in prison for engaging in what authorities called the most lucrative insider trading scheme in U.S. history. District Judge Paul Gardephe in New York also ordered Martoma, 40, to forfeit $9.3 million.
NEW YORK— The Federal Trade Commission is suing drugmakers AbbVie and Teva, saying they conspired to temporarily keep generic versions of AbbVie's low-testosterone drug AndroGel off the market.
NEW YORK, Sept 4- A federal judge on Thursday refused to throw out the insider trading conviction of former SAC Capital portfolio manager Mathew Martoma, saying the trial evidence "overwhelmingly demonstrated Martoma's guilt."
NEW YORK, Aug 14- A federal judge rejected billionaire investor Steven A. Cohen's bid to dismiss lawsuits by Elan Corp and Wyeth shareholders who claimed they lost money because his firm SAC Capital Advisors LP conducted insider trading in the drugmakers' stocks.
DUBLIN, July 30- Ireland is in the firing line from Washington again for luring U.S. companies to its shores for tax benefits, but despite contrite noises coming from Dublin, it has too much to lose to discourage U.S. firms bent on shifting their tax domiciles.
However, the report from the Generic Pharmaceutical Association said REMS have been used to prevent generic drugmakers from getting branded medicine to test their own versions, which is required to win FDA approval.
Medical technology group Medtronic Inc said last month that it plans to buy Covidien Plc, a rival based in low-tax Ireland. The research service said other inversions have been done in the past decade by Mallinckrodt Pharmaceuticals, Perrigo Co Plc, Actavis Plc and other companies, many of them rebasing for tax purposes to Ireland.
NEW YORK, June 27- Mathew Martoma, a former SAC Capital Advisors portfolio manager convicted of insider trading, should be sentenced to a "substantial" term of prison beyond the eight years recommended by probation officers, U.S. prosecutors argued Friday. In court papers filed in New York federal court, prosecutors urged U.S.
Mead Johnson Nutrition Co in 2011 saw its shares fall when stores pulled some powdered versions of its Enfamil product over concerns about infection, although the FDA later said a recall was not needed. The new rule, the FDA said, is aimed at establishing "good manufacturing practices" that many companies have already adopted voluntarily.
Some of Wednesday's midday movers:
There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.
In total, SAC Capital has agreed to pay $1.8 billion to resolve criminal and civil probes into insider trading. SAC Capital also agreed to be placed on probation for five years, and employ a compliance consultant, former federal prosecutor Bart Schwartz.
In total, SAC Capital has agreed to pay $1.8 billion to resolve criminal and civil probes into insider trading. SAC Capital also agreed to be placed on probation for five years, and employ a compliance consultant, former federal prosecutor Bart Schwartz. The sentencing marks the end of an era for SAC Capital, which by last year had managed $15 billion of assets.
The FTC has sued pharmaceutical companies $1 billion for delaying the sale of cheaper medicines after patents on brand-name drugs may have expired.
WASHINGTON, March 28- The U.S. Federal Trade Commission seeks a settlement of $1 billion or more from pharmaceutical companies it has sued for delaying the sale of cheaper medicines after patents on brand-name drugs may have expired, an FTC official told a legal conference on Friday.
A couple of stocks stand to gain over the next two weeks, Paul Hickey of Bespoke Investment Group says.
Events in Ukraine appear to be improving, but it may only be a matter of time before they take another turn for the worse. Are you prepared?
In his book "Get Rich Carefully," CNBC's "Mad Money" host explains how spotting long-term megatrends can help investors surf the wave of profitability.
Cramer believes there’s always opportunity in the market. You simply have to know where to look.
Perrigo CEO Joseph Papa provides insight on the current flu season, and how it plans on getting its name better known.